Inhibition of large intestinal cancers by celecoxib using a serial sacrifice technique

In Vivo

Volumn 20, Issue 4, 2006, Pages 453-458

  Toth, Bela ^a   Coles, Melissa ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cancer; Celecoxib; COX 2; Intestine; Prevention

Indexed keywords

1,2 DIMETHYLHYDRAZINE; CELECOXIB; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CANCER INHIBITION; CECUM CARCINOMA; COLON ADENOCARCINOMA; COLON POLYP; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; HISTOPATHOLOGY; LARGE INTESTINE CANCER; MOUSE; MOUSE STRAIN; NONHUMAN; RECTUM CARCINOMA; SURVIVAL RATE;

EID: 33746893732     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Toth B and Coles M: Prevention of tumors of the large intestine by celecoxib in mice. In Vivo 19: 661-664, 2005.
2. Talmadge JE, Hood KC, Zobel LC, Shafer LR, Coles M and Toth B: Chemoprevention by cyclooxygenase-2 inhibition prevents immature myeloid suppressor cell expansion. Carcinogenesis, submitted for publication.
3. Toth B, Malick L and Shimizu H: Production of intestinal and other tumors by 1,2-dimethylhydrazine dihydrochloride in mice. I. A light and transmission electron microscopic study of colonic neoplasms. Am J Pathol 84: 69-86, 1976.
4. Altman DG: Practical Statistics for Medical Research. Chapter 9: Comparing groups-continuous data. Chapman & Hall, New York, pp. 194-215, 1991.
5. Kawamori T, Rao CV, Seibert K and Reddy BS: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58: 409-412, 1998.
6. Jacoby RF, Seibert K, Cole CE, Kelloff G and Lubet RA: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60: 5040-5044, 2000.
7. Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, Seibert K and Rao CV: Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60: 293-297, 2000.
8. Brown WA, Skinner SA, Malcontenti-Wilson C, Misajon A, Dejong T, Vogiagis D and O'Brien PE: Non-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrotoxicity in a rat model. J Gastroenterol Hepatol 15: 1386-1392, 2000.
9. Brown WA, Skinner SA, Malcontenti-Wilson C, Vogiagis D and O'Brien PE: Non-steriodal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation. Gut 48: 660-666, 2001.
10. Rao CV, Indranie C, Simi B, Manning PT, Connor JR and Reddy BS: Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 62: 165-170, 2002.
11. Fischer SM, Lo H-H, Gordon GB, Seibert K, Kelloff G, Lubert RA and Conti CJ: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 25: 231-240, 1999.
12. Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, Kelloff GJ, Hill DL and Seibert K: Celecoxib inhibits n-butyl-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-334 rats. Cancer Res 60: 5599-5602, 2000.
13. Howe LR, Subbaramaiah K, Patel J, Masferrer J L, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AMC and Dannenberg AJ: Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 62: 5405-5407, 2002.
14. Fischer SM, Conti CJ, Viner J, Aldaz CM and Lubet RA: Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. Carcinogenesis 24: 945-952, 2003.
15. Hu PJ, Yu J, Zeng ZR, Leung WK, Lin HL, Tang BD, Bai HAC and Sung JJY: Chemoprevention of gastric cancer by celecoxib in rats. Gut 53: 195-200, 2004.
16. Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon G, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su L-K, Levin B, Godio L, Patterson S, Rodriguez-Bigas MA, Jester SL, King KL, Schumacher M, Abbruzzese J, DuBois RN, Hittelman WN, Zimmerman S, Sherman JW and Kelloff G: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Eng J Med 342: 1946-1952, 2000.
17. Phillips RKS, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su L-K, Sherman J, Kelloff G, Levin B, Steinbach G and FAP Study Group: A randomized, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50: 857-860, 2002.
18. Rahme E, Barkun AN, Toubouti Y and Bardou M: The cyclooxygenase-2 selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology 125: 404-412, 2003.
19. National Cancer Institute. News: NIH halts use of COX-2 inhibitors in large cancer prevention trial. http:www.nih.gov/news/pr/dec2004/od17Q&A.htm.
20. Couzin J: Massive trial of celebrex seeks to settle safety concerns. Science 310: 1890-1891, 2005.